

## **Clearside Biomedical, Inc. to Present at the 13th Congress of International Ocular Inflammation Society (IOIS) in San Francisco, CA**

September 22, 2015 12:12 AM ET

*Hosted by the Foster Ocular Immunology Society (FOIS)*

**Alpharetta, GA (September 22, 2015)** - Clearside Biomedical, Inc., a clinical-stage biopharmaceutical company developing first-in-class drug therapies uniquely positioned to treat blinding diseases of the retina and choroid, today announced Glenn Noronha, PhD, executive vice president of Research and Development of Clearside, will present a poster at the 13<sup>th</sup> Congress of International Ocular Inflammation Society (IOIS) September 25-27, 2015 in San Francisco, CA. Dr. Noronha's poster, **"Treating uveitis through suprachoroidal administration of triamcinolone acetonide: from bench through Phase 1/2 results"**, will be part of the Saturday morning poster session.

"Unlike intravitreal (IVT) delivery of drug therapy where drugs are dispersed throughout the eye, administration to the suprachoroidal space (SCS) enables drug to be administered to the retina and choroid, thereby providing the potential for a unique treatment paradigm for back-of-the-eye diseases," said Dr. Noronha. "For example, based on data from Clearside's completed Phase 1/2 study in non-infectious uveitis patients, we believe that SCS administration of corticosteroid in the eye using our SCS<sup>TM</sup> microinjector will provide robust differentiating efficacy while avoiding or reducing some of the side effects that are commonly associated with steroid usage."

### **About Uveitis**

Uveitis is one of the most frequent causes of blindness in the developed world. Based on prevalence data published in the journal *Ophthalmology* in 2004 and United States census data for 2010, it is estimated approximately 350,000 individuals in the United States suffer from some form of uveitis. Typically diagnosed in individuals between the ages of 20 and 50, uveitis can occur in one or both eyes and accounts for approximately 10% of cases of blindness in the United States, according to a study published in *Journal of Ophthalmology*. Uveitis can be either infectious or non-infectious. Non-infectious uveitis accounts for approximately 80% of all uveitis cases. Macular edema related to uveitis is the predominant cause of blindness or visual impairment among patients with uveitis, accounting for approximately 30% of cases of blindness in uveitis patients. Because uveitis can become chronic or recurrent if not adequately treated, some patients may become refractory, or unresponsive, to treatment, leading to irreversible blindness.

### **About Clearside Biomedical, Inc.**

Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a clinical-stage biopharmaceutical company developing first-in-class drug therapies uniquely positioned to treat chronic, blinding diseases of the eye. Clearside's product candidates focus on diseases affecting the retina and the choroid, especially diseases associated with macular edema. Visit [www.clearsidebio.com](http://www.clearsidebio.com) for more information.

### **Contacts**

Clearside Biomedical, Inc.  
Charles Deignan, 678-270-4005  
[charlie.deignan@clearsidebio.com](mailto:charlie.deignan@clearsidebio.com)